[HTML][HTML] Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody
C Wiebe, IW Gibson, TD Blydt-Hansen… - American Journal of …, 2015 - Elsevier
Understanding rates and determinants of clinical pathologic progression for recipients with
de novo donor-specific antibody (dnDSA), especially subclinical dnDSA, may identify
surrogate endpoints and inform clinical trial design. A consecutive cohort of 508 renal
transplant recipients (n= 64 with dnDSA) was studied. Recipients (n= 388) without dnDSA or
dysfunction had an eGFR decline of− 0.65 mL/min/1.73 m 2/year. In recipients with dnDSA,
the rate eGFR decline was significantly increased prior to dnDSA onset (− 2.89 vs.− 0.65 …
de novo donor-specific antibody (dnDSA), especially subclinical dnDSA, may identify
surrogate endpoints and inform clinical trial design. A consecutive cohort of 508 renal
transplant recipients (n= 64 with dnDSA) was studied. Recipients (n= 388) without dnDSA or
dysfunction had an eGFR decline of− 0.65 mL/min/1.73 m 2/year. In recipients with dnDSA,
the rate eGFR decline was significantly increased prior to dnDSA onset (− 2.89 vs.− 0.65 …